Last reviewed · How we verify
Non-TKIs
At a glance
| Generic name | Non-TKIs |
|---|---|
| Sponsor | Bayer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC (EARLY_PHASE1)
- A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC (PHASE1, PHASE2)
- Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy (PHASE2)
- ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs (PHASE2)
- Therapy for Advanced NSCLC With EGFR 19delins Mutation (EARLY_PHASE1)
- A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC (PHASE1)
- Phase 3 Clinical Study of AK112 for NSCLC Patients (PHASE3)
- Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Non-TKIs CI brief — competitive landscape report
- Non-TKIs updates RSS · CI watch RSS
- Bayer portfolio CI